July 2026 Pacing
—
Month-over-Month · July vs. June 2026
- Most lines overdelivered in July, for a total of 87,354 bonus impressions. Wegovy Obesity came in slightly under at 94.2% — the one line we paused mid-month for a creative fix — and its remaining 17,314 impressions roll forward into August.
- Total delivery came in at 2.76M impressions against 2.52M in June. Azilsartan's launch accounts for the increase — the established lines each held their June volume within two percent.
- Azilsartan's first full month delivered 236,558 impressions, 110.4% of its July goal, for +22,272 impressions of added value.
- Xopenex video quality improved: OLV completion rose to 91.2% from 88.5% in June, and CTV held at 98.4%. Display click-through also stepped up, to 0.43% from 0.40%.
- Click-through was mixed against June. Tarpeyo improved to 0.28% and Wegovy MASH to 0.20%; Ozempic eased to 0.17% and Wegovy Obesity to 0.14%. OLV eased to 0.027% from 0.045% even as its completion rate climbed.
Health Monitor
Wegovy MASH
Health Monitor
Ozempic
Health Monitor
Tarpeyo
Launched May 19, 2026
Health Monitor
Wegovy Obesity
Lupin Pharmaceuticals
Xopenex
Lupin Pharmaceuticals
Azilsartan
HCP Display · Launched Jul 1, 2026